Arcus Biosciences has announced a clinical trial partnership with AstraZeneca to assess the combination of casdatifan (AB521) ...

US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer ...

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...

Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdatifan leading the way. See why I rate RCUS ...

The five-year loan and four-year interest-only period may each be extended another year should Arcus initiate Phase III trials for its cancer therapies, a HIF-2α inhibitor casdatifan and the CD73 ...

Arcus Biosciences Inc. recently disclosed the chemical structure of AB-521 (casdatifan), an orally available small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α) in early clinical ...

The additional capital strengthens Arcus’s balance sheet and increases flexibility to rapidly advance casdatifan, its potential best-in-class HIF-2a inhibitor. Arcus plans to present data from ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on RCUS stock, giving a Buy rating on September 16. Daina ...

Blasts Shake Beirut as Israel Targets Hezbollah Leaders, Officials Say Israeli officials said planes bombed a bunker where senior Hezbollah officials were meeting, including the presumed successor ...

Facility adds operational flexibility and provides funding for the recently announced Phase 3 PEAK-1 study for casdatifan. $150 million committed, of which $50 million was drawn at closing and the ...